Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 4/20 | 0.47 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | BRS3 | P32247 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7895778 | 0.86 | CLK4 (0.51) | CLK4DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL10168733 | 0.83 | PARP11 (0.66) | GRM5PARP11PARP10 | |
| SCHEMBL26768108 | 0.83 | RYR2 (0.42) | GRM5ALDH1A1BRS3KDR | |
| SCHEMBL12193961 | 0.82 | CA12 (0.48) | CLK4DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL4597521 | 0.82 | CA12 (0.48) | CLK4DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL30452325 | 0.82 | CA12 (0.48) | CLK4DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL30073094 | 0.82 | CA12 (0.48) | CLK4DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL12194628 | 0.81 | DAPK3 (0.46) | CLK4DAPK3NTRK1PIM1FLT3 | |
| SCHEMBL27446376 | 0.80 | PARP11 (0.55) | GSK3BGRM5PARP11NPC1ALDH1A1 | |
| SCHEMBL28007031 | 0.79 | CLK4 (0.43) | CLK4DAPK3NTRK1PIM1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119122-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023178181-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-20210147402-A1 | COMPOUNDS AND METHODS OF PREPARING COMPOUNDS S1P1 MODULATORS | TREVENA, INC. | 2021-05-20 | — | — | US | disclosed |
| EP-3233858-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| US-9896443-B2 | Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-02-20 | — | — | US | disclosed |
| WO-2017214005-A1 | 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170247326-A1 | Substituted Pyrrolidine Carboxamide Compounds | Epizyme, Inc. (US) | 2017-08-31 | — | — | US | disclosed |
| WO-2010065717-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| WO-2010034740-A1 | (R)-3-(N,N-DIMETHYLAMINO)PYRROLIDINE DERIVATIVES | PALAU PHARMA, S.A. (ES) | 2010-04-01 | — | — | WO | disclosed |
| US-20090298836-A1 | Thiadiazole modulators of PKB | AMGEN INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090275592-A1 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | CLK4 1842/4885DAPK3 869/4885NTRK1 1129/4885 |
| US-20090298836-A1 | Thiadiazole modulators of PKB | PDK1, PDK2, MTOR | CLK4 948/4885DAPK3 509/4885NTRK1 4327/4885 |
| US-20090275592-A1 | Heterocyclic modulators of PKB | MTOR, PDK1, EIF4EBP1 | CLK4 1818/4885DAPK3 895/4885NTRK1 4672/4885 |
| US-20210147402-A1 | COMPOUNDS AND METHODS OF PREPARING COMPOUNDS S1P1 MODULATORS | S1PR1, S1PR2, S1PR5 | CLK4 3756/4885DAPK3 2332/4885NTRK1 906/4885 |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | CLK4 2409/4885DAPK3 388/4885NTRK1 3852/4885 |
| US-20170247326-A1 | Substituted Pyrrolidine Carboxamide Compounds | SMYD3, SMYD2, SMURF2 | CLK4 3337/4885DAPK3 904/4885NTRK1 4096/4885 |
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | CLK4 818/4885DAPK3 699/4885NTRK1 3186/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | CLK4 1038/4885DAPK3 915/4885NTRK1 4168/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | CLK4 2866/4885DAPK3 2303/4885NTRK1 991/4885 |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | SYK, JAK2, BTK | CLK4 965/4885DAPK3 422/4885NTRK1 1700/4885 |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | HGF, MET, BLK | CLK4 658/4885DAPK3 854/4885NTRK1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.